Other

Amgen Inc.

Aventis Pharmaceuticals Inc.

Carl Edwards, Iii

David R Borcherding

Eric F Fisher

Gary Kieft

Douglas L Cole

Tong Zhou

Ronald E Esser

John D Mountz

Huang-Ge Zhang

Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor necrosis binding proteins by recombinant genetic engineering techniques.

Nucleic acids encoding truncated soluble tumor necrosis factor

Truncated soluble tumor necrosis factor type-I and type-II receptors

Carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines

Trans cyclopentanyl purine analogs useful as immunosuppressants

The present invention provides a method of increasing adenoviral gene expression in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of tumor necrosis factor binding protein. Also provided is a various method of method of reducing an inflammatory response associated with adenoviral administration in a tissue of an animal, comprising the step of administering to said animal a pharmacologically effective dose of tumor necrosis factor binding protein.

Method for the augmentation of gene expression

Growing community of inventors

Superior, CO, United States of America

Carl Edwards, Iii